ALN1003 / Alaunos Therap - LARVOL DELTA

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study (Business Insider) - "...in the 48-day DIO Study 1, ALN1003-treated animals had lower liver weight than controls after adjustment for body fat percentage in a standard ANCOVA analysis (p=0.000005), with the same conclusion confirmed using heteroscedasticity-robust HC3 standard errors as a sensitivity analysis (p=0.000015). This statistical finding indicates that the lower liver weight associated with ALN1003 treatment was not fully explained by measured body fat percentage in this model...The body-fat-adjusted liver-weight finding is directionally consistent with a previously reported blinded pilot pathology review of selected liver samples...The HOMA-IR finding remained statistically significant after adjustment for percentage body fat (ANCOVA p=0.0006; HC3 robust sensitivity p=0.0014)."

Preclinical • Metabolic Dysfunction-Associated Steatohepatitis • Obesity